Skip to main content

Guidelines for the Delineation of Lymphatic Target Volumes in Prostate Cancer

  • 1026 Accesses

Abstract

The incidence of regional lymph node (LN) involvement in patients with prostate cancer depends on several factors like the tumor size and the Gleason score (GS). The risk of LN involvement is <10% in low-risk disease. A number of models were developed in order to predict the risk of LN involvement which helps the physicians to decide whether to perform a staging lymphadenectomy or LN irradiation. In this chapter, we will review the current guidelines for the delineation of lymphatic target volumes in prostate cancer.

Keywords

  • Prostate cancer
  • Pelvic lymph node delineation
  • Pelvic radiotherapy

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-319-56114-1_15
  • Chapter length: 10 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   139.00
Price excludes VAT (USA)
  • ISBN: 978-3-319-56114-1
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   179.99
Price excludes VAT (USA)
Hardcover Book
USD   179.99
Price excludes VAT (USA)
Fig. 15.1

References

  1. Fowler JE Jr, Whitmore WF Jr. The incidence and extent of pelvic lymph node metastases in apparently localized prostatic cancer. Cancer. 1981;47(12):2941–5.

    CrossRef  PubMed  Google Scholar 

  2. Pisansky TM, Zincke H, Suman VJ, Bostwick DG, Earle JD, Oesterling JE. Correlation of pretherapy prostate cancer characteristics with histologic findings from pelvic lymphadenectomy specimens. Int J Radiat Oncol Biol Phys. 1996;34(1):33–9.

    CAS  CrossRef  PubMed  Google Scholar 

  3. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993;150(1):110–4.

    CAS  CrossRef  PubMed  Google Scholar 

  4. Bishoff JT, Reyes A, Thompson IM, Harris MJ, St Clair SR, Gomella L, et al. Pelvic lymphadenectomy can be omitted in selected patients with carcinoma of the prostate: development of a system of patient selection. Urology. 1995;45(2):270–4.

    CAS  CrossRef  PubMed  Google Scholar 

  5. Link RE, Morton RA. Indications for pelvic lymphadenectomy in prostate cancer. Urol Clin North Am. 2001;28(3):491–8.

    CAS  CrossRef  PubMed  Google Scholar 

  6. Stock RG, Stone NN, Ianuzzi C, Unger P. Seminal vesicle biopsy and laparoscopic pelvic lymph node dissection: implications for patient selection in the radiotherapeutic management of prostate cancer. Int J Radiat Oncol Biol Phys. 1995;33(4):815–21.

    CAS  CrossRef  PubMed  Google Scholar 

  7. Rees MA, Campbell S, Kleian EA, et al. Validation of a model for predicting metastatic disease in the pelvic lymph nodes of patients with clinically localized prostate cancer. J Urol. 1996;155:487. (abst).

    Google Scholar 

  8. Roach M. Equations for predicting the pathologic state of men with localized prostate cancer using the preoperative prostate specific antigen. J Urol. 1993;150:1923–4.

    CrossRef  PubMed  Google Scholar 

  9. Gervasi LA, Mata J, Easley JD, Wilbanks JH, Seale-Hawkins C, Carlton CE Jr, et al. Prognostic significance of lymph nodal metastases in prostate cancer. J Urol. 1989;142(2 Pt 1):332–6.

    CAS  CrossRef  PubMed  Google Scholar 

  10. Cheng L, Zincke H, Blute ML, Bergstralh EJ, Scherer B, Bostwick DG. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer. 2001;91(1):66–73.

    CAS  CrossRef  PubMed  Google Scholar 

  11. Prout GR Jr, Heaney JA, Griffin PP, Daly JJ, Shipley WU. Nodal involvement as a prognostic indicator in patients with prostatic carcinoma. J Urol. 1980;124(2):226–31.

    CrossRef  PubMed  Google Scholar 

  12. Golimbu M, Provet J, Al-Askari S, Morales P. Radical prostatectomy for stage D1 prostate cancer. Prognostic variables and results of treatment. Urology. 1987;30(5):427–35.

    CAS  CrossRef  PubMed  Google Scholar 

  13. UICC. TNM supplement. 3rd ed. 2003.

    Google Scholar 

  14. Dirix P, Haustermans K, Junius S, Withers R, Oyen R, Van Poppel H. The role of whole pelvic radiotherapy in locally advanced prostate cancer. Radiother Oncol. 2006;79(1):1–14.

    CrossRef  PubMed  Google Scholar 

  15. Asbell SO, Martz KL, Shin KH, Sause WT, Doggett RL, Perez CA, et al. Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG #77-06, a phase III study for T1BN0M0 (A2) and T2N0M0 (B) prostate carcinoma. Int J Radiat Oncol Biol Phys. 1998;40(4):769–82.

    CAS  CrossRef  PubMed  Google Scholar 

  16. Roach M 3rd, DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003;21(10):1904–11.

    CrossRef  PubMed  Google Scholar 

  17. Roach M, Yan Y, Lawton CA, Hsu IJ, Lustig RA, Jones CU, et al. Radiation Therapy Oncology Group (RTOG) 9413: randomized trial comparing whole pelvic radiotherapy (WPRT) to prostate only (PORT) and neoadjuvant hormone therapy (NHT) to adjuvant hormone therapy (AHT). J Clin Oncol. 2012;30(suppl 5):96.

    CrossRef  Google Scholar 

  18. Pommier P, Chabaud S, Lagrange JL, Richaud P, Lesaunier F, Le Prise E, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol. 2007;25(34):5366–73.

    CrossRef  PubMed  Google Scholar 

  19. Pommier P, Chabaud S, Lagrange JL, Richaud P, Le Prise E, Wagner JP, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Update of the long-term survival results of the GETUG-01 randomized study. Int J Radiat Oncol Biol Phys. 2016;96(4):759–69.

    CrossRef  PubMed  Google Scholar 

  20. Murthy V, Lewis S, Sawant M, Paul SN, Mahantshetty U, Shrivastava SK. Incidental dose to pelvic nodal regions in prostate-only radiotherapy. Technol Cancer Res Treat. 2017;16(2):211–7.

    CrossRef  PubMed  Google Scholar 

  21. Saksena MA, Kim JY, Harisinghani MG. Nodal staging in genitourinary cancers. Abdom Imaging. 2006;31(6):644–51.

    CAS  CrossRef  PubMed  Google Scholar 

  22. Koh DM, Hughes M, Husband JE. Cross-sectional imaging of nodal metastases in the abdomen and pelvis. Abdom Imaging. 2006;31(6):632–43.

    CAS  CrossRef  PubMed  Google Scholar 

  23. Chapet O, Enachescu C, Lorchel F. Pelvic irradiation in prostate cancer: what place for what volumes? Cancer Radiother. 2013;17(5–6):562–5.

    CAS  CrossRef  PubMed  Google Scholar 

  24. Padhani AR. Lymph Nodes. In: Nicholson T, editor. Recommendations for cross-sectional imaging in cancer management. London: The Royal College of Radiologists; 2014.

    Google Scholar 

  25. Lawton CA, Michalski J, El-Naqa I, Buyyounouski MK, Lee WR, Menard C, et al. RTOG GU radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2009;74(2):383–7.

    CrossRef  PubMed  Google Scholar 

  26. Meijer HJ, Fortuin AS, van Lin EN, Debats OA, Alfred Witjes J, Kaanders JH, et al. Geographical distribution of lymph node metastases on MR lymphography in prostate cancer patients. Radiother Oncol. 2013;106(1):59–63.

    CrossRef  PubMed  Google Scholar 

  27. Spratt DE, Vargas HA, Zumsteg ZS, Golia Pernicka JS, Osborne JR, Pei X, et al. Patterns of lymph node failure after dose-escalated radiotherapy: implications for extended pelvic lymph node coverage. Eur Urol. 2017;71(1):37–43.

    CrossRef  PubMed  Google Scholar 

  28. Shih HA, Harisinghani M, Zietman AL, Wolfgang JA, Saksena M, Weissleder R. Mapping of nodal disease in locally advanced prostate cancer: rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy. Int J Radiat Oncol Biol Phys. 2005;63(4):1262–9.

    CrossRef  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Pervin Hurmuz M.D. .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Ozyigit, G., Yazici, G., Sari, S.Y., Gultekin, M., Hurmuz, P., Akyol, F. (2017). Guidelines for the Delineation of Lymphatic Target Volumes in Prostate Cancer. In: Ozyigit, G., Selek, U. (eds) Principles and Practice of Urooncology. Springer, Cham. https://doi.org/10.1007/978-3-319-56114-1_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56114-1_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56113-4

  • Online ISBN: 978-3-319-56114-1

  • eBook Packages: MedicineMedicine (R0)